8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 16, 2025)

Filed July 16, 2025For Securities:JNJ

Summary

Johnson & Johnson (JNJ) has filed an 8-K report detailing its second-quarter financial results for the period ended June 29, 2025. The filing primarily references a press release and supplementary financial data, providing investors with key operational and financial performance metrics for the recently concluded quarter. This report is crucial for understanding the company's recent sales trends and earnings, which are vital indicators of its ongoing business health and strategic execution within its diverse segments, including pharmaceuticals, medical devices, and consumer health. Investors should review the attached exhibits for a comprehensive understanding of the company's performance against expectations and its trajectory for the remainder of the fiscal year. The provided documentation includes the press release announcing Q2 2025 results and unaudited comparative supplementary sales data along with condensed consolidated statements of earnings. These materials are essential for evaluating Johnson & Johnson's financial condition and operational results, allowing for comparisons to prior periods and potentially to industry benchmarks. The market will be closely watching these figures to assess the impact of various economic factors, competitive pressures, and the company's strategic initiatives on its bottom line and revenue generation.

Key Highlights

  • 1JNJ filed an 8-K on July 15, 2025, reporting Q2 2025 financial results ended June 29, 2025.
  • 2The filing is primarily based on a press release issued on July 16, 2025, detailing sales and earnings.
  • 3Investors can access detailed financial information through Exhibit 99.1 (Press Release) and Exhibit 99.2 (Supplementary Sales Data and Condensed Consolidated Statement of Earnings).
  • 4The report covers the company's financial performance for the second fiscal quarter.
  • 5Key financial metrics such as sales and earnings for the quarter are disclosed.
  • 6The filing provides context for understanding JNJ's operational performance and financial condition during the specified period.

Frequently Asked Questions